Stockscreener 앱 받기
1.12
3.45%
-0.04
시장 영업 전:
1.12
전일 마감가:
$1.16
열려 있는:
$1.15
하루 거래량:
191.76K
Relative Volume:
0.25
시가총액:
$20.69M
수익:
-
순이익/손실:
$-39.14M
주가수익비율:
-0.1876
EPS:
-5.97
순현금흐름:
$-28.20M
1주 성능:
-5.08%
1개월 성능:
+1.36%
6개월 성능:
+21.74%
1년 성능:
-60.84%
1일 변동 폭
$1.11
$1.1957
1주일 범위
$1.10
$1.2499
52주 변동 폭
$0.65
$5.95
Citius Pharmaceuticals Inc Stock (CTXR) Company Profile
명칭
Citius Pharmaceuticals Inc
전화
(908) 967-6676
주소
11 COMMERCE DRIVE, CRANFORD, NJ
CTXR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CTXR
Citius Pharmaceuticals Inc
|
1.12 | 21.43M | 0 | -39.14M | -28.20M | -5.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Citius Pharmaceuticals Inc Stock (CTXR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-30 | 업그레이드 | D. Boral Capital | Hold → Buy |
| 2021-11-30 | 개시 | Maxim Group | Buy |
Citius Pharmaceuticals Inc 주식(CTXR)의 최신 뉴스
Citius Oncology closes $18 million in offerings to support LYMPHIR launch - Investing.com Nigeria
Citius Oncology Announces Closing of $18 Million Concurrent Regi - GuruFocus
Citius Oncology closes $18 million in offerings to support LYMPHIR launch By Investing.com - Investing.com South Africa
Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules - Barchart.com
Citius Oncology shares sink after announcing $18M fundraising deal - MSN
Citius Oncology (Nasdaq: CTOR) sets $18M stock deal at $1.09 to back LYMPHIR launch - Stock Titan
Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules - Sahm
Aug Selloffs: Is Citius Pharmaceuticals Inc stock positioned for digital transformationPortfolio Gains Summary & Free Real-Time Volume Trigger Notifications - moha.gov.vn
Is Citius Pharmaceuticals Inc. (47N0) stock good for wealth creationJuly 2025 Momentum & Safe Investment Capital Preservation Plans - Newser
How Citius Pharmaceuticals Inc. (47N0) stock reacts to fiscal policiesJuly 2025 Big Picture & Trade Opportunity Analysis - Newser
CTXR: Analyst Jason Kolbert Maintains 'Buy' Rating with $6 Price Target | CTXR Stock News - GuruFocus
Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim - The Malaysian Reserve
Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Midd - GuruFocus
Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim – Company AnnouncementFT.com - Financial Times
How supply shortages influence Citius Pharmaceuticals Inc. (47N0) stockWeekly Market Outlook & AI Powered Trade Plan Recommendations - Newser
How Citius Pharmaceuticals Inc. (47N0) stock responds to bond market2025 Investor Takeaways & AI Enhanced Trading Signals - Newser
Cutaneous T-cell Lymphoma Market Expected to Experience Major Growth by 2032, According to DelveInsight | Innate Pharma, Galderma R&D, Kyowa Kirin, Citius Pharma, Soligenix, 4SC AG, oligenix, Ligand - Barchart.com
Citius Oncology launches Lymphir treatment for rare lymphoma - NJBIZ
How Citius Pharmaceuticals Inc. (47N0) stock reacts to new regulations2025 Analyst Calls & Momentum Based Trading Signals - Newser
Is Citius Pharmaceuticals Inc. (47N0) stock vulnerable to rate hikesDollar Strength & Capital Efficiency Focused Ideas - Newser
Citius Oncology enters distribution services agreement with Cardinal Health - MSN
Why Citius Pharmaceuticals Inc. (47N0) stock is a must watch tickerWeekly Loss Report & Reliable Entry Point Trade Alerts - Newser
Citius Oncology Launches LYMPHIR, The First CTCL Systemic Therapy In Over 7 Years - Nasdaq
Citius Pharmaceuticals Launches LYMPHIR for T-Cell Lymphoma - MSN
Will Citius Pharmaceuticals Inc. (47N0) stock boost dividends furtherProduct Launch & Stepwise Trade Signal Implementation - Newser
How Citius Pharmaceuticals Inc. (47N0) stock moves in volatile trading sessions - Newser
Citius Oncology Announces U.S. Commercial Launch of LYMPHIRtm, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL) - Lelezard
CTORCitius Oncology, Inc. Latest Stock News & Market Updates - Stock Titan
Citius Pharmaceuticals, Inc. Launches LYMPHIR for CTCL Treatment - TradingView — Track All Markets
Citius Oncology Announces U.S. Commercial Launch of LYMPHIR, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL) - Finviz
Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL) – Company AnnouncementFT.com - Financial Times
Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL) - Sahm
Citius Oncology (Nasdaq: CTOR) debuts LYMPHIR in over $400 million U.S. CTCL market - Stock Titan
Why Citius Pharmaceuticals Inc. stock remains resilientIPO Watch & AI Forecasted Entry/Exit Points - BỘ NỘI VỤ
Citius Oncology Deploys AI Platform to Amplify the Performance of its Commercial Team Ahead of LYMPHIR Launch - Aktiellt
Citius Oncology to Exhibit at the 67th American Society of Hematology (ASH) Annual Meeting - 富途牛牛
Citius Oncology (NASDAQ: CTOR) to Exhibit LYMPHIR for CTCL Patients at ASH 2025 - Stock Titan
Butterfly Network, Citius Pharma Drive Biotech Momentum In After-Hours Trading - Nasdaq
Citius Oncology to advance LYMPHIR launch with AI technology By Investing.com - Investing.com Nigeria
Citius Oncology to Advance Commercial Launch of LYMPHIR™ with Verix AI Integration - Placera.se
Citius Oncology stock soars on expanded AI collaboration for LYMPHIR launch - Investing.com
Citius Oncology to advance LYMPHIR launch with AI technology - Investing.com India
Citius Oncology (Nasdaq: CTOR) taps Verix AI to support Q4 2025 LYMPHIR CTCL launch - Stock Titan
Can Citius Pharmaceuticals Inc. (47N0) stock sustain free cash flow - newser.com
How Citius Pharmaceuticals Inc. stock reacts to Fed rate cutsStop Loss & Weekly High Potential Stock Alerts - newser.com
Can Citius Pharmaceuticals Inc. (47N0) stock withstand sector downturns2025 Top Decliners & Long-Term Safe Investment Plans - newser.com
Is Citius Pharmaceuticals Inc. (47N0) stock good for long term investingMarket Activity Summary & Daily Entry Point Trade Alerts - newser.com
Citius Pharmaceuticals Inc (CTXR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.08%
0.91%
자본화:
|
볼륨(24시간):